Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from uniQure ( (QURE) ).
On September 22, 2025, uniQure N.V. entered into an amendment with Hercules Capital to their existing loan agreement, allowing for an additional $175 million in term loans. This amendment is intended to refinance existing loans and support general corporate purposes, potentially impacting uniQure’s financial flexibility and operational capacity in the biotechnology sector.
The most recent analyst rating on (QURE) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on uniQure stock, see the QURE Stock Forecast page.
Spark’s Take on QURE Stock
According to Spark, TipRanks’ AI Analyst, QURE is a Neutral.
uniQure’s overall stock score reflects significant financial challenges, with declining revenues and a weak balance sheet being major concerns. Despite these issues, the stock shows positive technical momentum, and the company has made notable clinical advancements, particularly with AMT-130. However, the negative P/E ratio and lack of dividend yield limit its valuation appeal.
To see Spark’s full report on QURE stock, click here.
More about uniQure
uniQure N.V. operates in the biotechnology industry, focusing on developing gene therapies. The company is known for its work on innovative treatments for genetic disorders, with a particular emphasis on therapies for rare diseases.
Average Trading Volume: 2,247,225
Technical Sentiment Signal: Buy
Current Market Cap: $2.61B
See more insights into QURE stock on TipRanks’ Stock Analysis page.